Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

NCT00791778 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

246

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)
DRUG: Placebo

Sponsor

Bayer